Effets endocriniens et métaboliques des antihypertenseurs: effets pléiotropes et conséquences dans le syndrome métabolique [Metabolic and endocrine effects of antihypertensive drugs]

Détails

ID Serval
serval:BIB_CCA8C0813F37
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Effets endocriniens et métaboliques des antihypertenseurs: effets pléiotropes et conséquences dans le syndrome métabolique [Metabolic and endocrine effects of antihypertensive drugs]
Périodique
Revue medicale suisse
Auteur⸱e⸱s
Martin-Du Pan R., Pruijm M.
ISSN
1660-9379 (Print)
ISSN-L
1660-9379
Statut éditorial
Publié
Date de publication
14/03/2007
Peer-reviewed
Oui
Volume
3
Numéro
102
Pages
681-684,687-688,690-691
Langue
français
Notes
Publication types: Journal Article ; Review
Publication Status: ppublish
Résumé
Antihypertensive therapy has been associated with 35 to 40% reduction in stroke incidence and 20 to 25% reduction in myocardial infarction. Antihypertensive drugs have various metabolic and endocrine activities. Their effect on electrolytes and hormones which modify the serum levels of electrolytes (such as aldosterone, angiotensine II and brain natriuretic peptide) is reviewed. Antihypertensive drugs may also modify risk factors for cardiovascular disease such as cholesterol, CRP hs, as well as urate acid and insulin resistance. Diuretics and betablockers increase this resistance whereas, it is decreased by certain enzyme conversion inhibitors and certain angiotensine II receptor blockers, partially through adiponectin release. Endocrine side effects of antihypertensive drugs such as weight gain, diabetes, gout, osteoporosis, impotence are discussed. They may decrease adherence to medication. Therefore we recommend if possible a low dose combination of antihypertensive drugs.
Mots-clé
Antihypertensive Agents/pharmacology, Endocrine Glands/drug effects, Humans, Metabolic Syndrome/etiology, Metabolism/drug effects
Pubmed
Création de la notice
31/12/2020 13:48
Dernière modification de la notice
03/06/2023 6:51
Données d'usage